Tasman Therapeutics, Inc. (Tasman) has announced plans to raise $175 million in Series A funding to support the late-stage clinical development and eventual commercialization of R-107. This innovative ...

EU approves AstraZeneca’s Imfinzi-in combo with chemotherapy to treat patients with resectable non-small cell lung cancer ...

like AstraZeneca's Enhertu (trastuzumab deruxtecan), which required treatment discontinuation. There were nine deaths across the two dose groups, with one deemed treatment-related (in the 12 mg/kg ...

The first two toddlers treated in the dose escalation trial of SENS-501 ... celebrating two approvals for cancer drugs Imfinzi and Enhertu in the EU as it faces increased competition to ...

(RTTNews) - AstraZeneca Plc. (AZN.L, AZN) and Daiichi Sankyo's (DSKYF.PK) Enhertu (trastuzumab deruxtecan) has been approved in the European Union as a treatment for adults with advanced breast ...

The European Commission (EC) has approved Daiichi Sankyo and AstraZeneca’s Enhertu (trastuzumab deruxtecan) for use as a single agent to treat adults with unresectable or metastatic hormone ...

AstraZeneca PLC (LSE:LON:AZN), a pharmaceutical giant with a market capitalization of $224 billion and an impressive gross profit margin of 82%, announced today that its drug Enhertu has been ...

AstraZeneca PLC (LSE:LON:AZN), a pharmaceutical giant with a market capitalization of $224 billion and an impressive gross profit margin of 82%, announced today that its drug Enhertu has been approved ...

AstraZeneca (AZ) and Daiichi Sankyo’s Enhertu (trastuzumab deruxtecan) has been approved by the European Commission (EC) to treat a broader population of HER2-low breast cancer patients. The drug has ...

Enhertu reduced the risk of disease progression or death by 38% vs. chemotherapy in HR+, HER2-low metastatic breast cancer patients. AstraZeneca owes Daiichi Sankyo a $125 million milestone ...

The Cambridge, England-based pharmaceuticals firm said Enhertu, or trastuzumab deruxtecan, has been approved in the EU as a therapy for adult patients with unresectable or metastatic hormone ...